These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33729079)

  • 1. Cost-utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck.
    Leung HW; Lang HC; Wang SY; Leung JH; Chan AL
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):489-495. PubMed ID: 33729079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer.
    Kim H; Vargo JA; Beriwal S; Clump DA; Ohr JP; Ferris RL; Heron DE; Huq MS; Smith KJ
    Head Neck; 2018 Aug; 40(8):1743-1751. PubMed ID: 29537684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world cost-effectiveness of cetuximab in locally advanced squamous cell carcinoma of the head and neck.
    van der Linden N; van Gils CW; Pescott CP; Buter J; Vergeer MR; Groot CA
    Eur Arch Otorhinolaryngol; 2015 Aug; 272(8):2007-16. PubMed ID: 24943191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Greenhalgh J; Bagust A; Boland A; Fleeman N; McLeod C; Dundar Y; Proudlove C; Shaw R
    Health Technol Assess; 2009 Oct; 13 Suppl 3():49-54. PubMed ID: 19846029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.
    Leung HW; Liu CF; Chan AL
    Radiat Oncol; 2016 May; 11():69. PubMed ID: 27193904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases.
    Kim H; Rajagopalan MS; Beriwal S; Huq MS; Smith KJ
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):556-63. PubMed ID: 25680599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant stereotactic body radiotherapy±cetuximab following salvage surgery in previously irradiated head and neck cancer.
    Vargo JA; Kubicek GJ; Ferris RL; Duvvuri U; Johnson JT; Ohr J; Clump DA; Burton S; Heron DE
    Laryngoscope; 2014 Jul; 124(7):1579-84. PubMed ID: 24123056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysis.
    Ye D; Liang X; Chen X; Li Y
    Sci Rep; 2024 Mar; 14(1):6807. PubMed ID: 38514766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of cetuximab concurrent with radiotherapy for patients with locally advanced head and neck cancer in Taiwan: a decision-tree analysis.
    Chan AL; Leung HW; Huang SF
    Clin Drug Investig; 2011 Oct; 31(10):717-26. PubMed ID: 21744880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of patient-reported quality-of-life outcomes following SBRT ± cetuximab for locally-recurrent, previously-irradiated head and neck cancer.
    Vargo JA; Heron DE; Ferris RL; Rwigema JC; Wegner RE; Kalash R; Ohr J; Kubicek GJ; Burton S
    Radiother Oncol; 2012 Jul; 104(1):91-5. PubMed ID: 22677037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of nivolumab in the treatment of head and neck cancer.
    Hirschmann A; Lupatsch JE; Schwenkglenks M; Panje CM; Matter-Walstra K; Espeli V; Dedes KJ; Siano M;
    Oral Oncol; 2018 Dec; 87():104-110. PubMed ID: 30527224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study.
    Heron DE; Rwigema JC; Gibson MK; Burton SA; Quinn AE; Ferris RL
    Am J Clin Oncol; 2011 Apr; 34(2):165-72. PubMed ID: 20686406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer.
    Murphy JD; Chang DT; Abelson J; Daly ME; Yeung HN; Nelson LM; Koong AC
    Cancer; 2012 Feb; 118(4):1119-29. PubMed ID: 21773972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck.
    Vargo JA; Ferris RL; Ohr J; Clump DA; Davis KS; Duvvuri U; Kim S; Johnson JT; Bauman JE; Gibson MK; Branstetter BF; Heron DE
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):480-8. PubMed ID: 25680594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiotherapy plus cetuximab for previously irradiated un-resectable head and neck cancer.
    Huang TL; Chuang HC; Tsai MH; Chien CY; Su YY; Lin YT; Yang CH; Lai CC; Li SH; Fang FM
    Biomed J; 2022 Oct; 45(5):838-846. PubMed ID: 34749016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.
    Haddad R; Cohen EEW; Venkatachalam M; Young K; Singh P; Shaw JW; Korytowsky B; Abraham P; Harrington KJ
    J Med Econ; 2020 May; 23(5):442-447. PubMed ID: 31928375
    [No Abstract]   [Full Text] [Related]  

  • 17. Pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy to treat recurrent or metastatic head and neck squamous cell carcinoma: An updated KEYNOTE-048 based cost-effectiveness analysis.
    She L; Tian K; Han J; Zuo W; Wang Z; Zhang N
    Oral Oncol; 2022 Jun; 129():105871. PubMed ID: 35483156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
    Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M
    Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck.
    Griffin S; Walker S; Sculpher M; White S; Erhorn S; Brent S; Dyker A; Ferrie L; Gilfillan C; Horsley W; Macfarlane K; Thomas S
    Health Technol Assess; 2009 Jun; 13 Suppl 1():49-54. PubMed ID: 19567214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis of Upfront SBRT for Oligometastatic Stage IV Non-Small Cell Lung Cancer Based on Mutational Status.
    Kim H; Vargo JA; Ling DC; Beriwal S; Smith KJ
    Am J Clin Oncol; 2019 Nov; 42(11):837-844. PubMed ID: 31644441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.